Tag Archives: Life Science Leader

Do Outcomes Matter When There Is Chronic Misalignment?

synthetic biology

This piece by Allan L. Shaw was originally published in Life Science Leader. With over $3 trillion in annual healthcare spending, a relatively young population, and shorter life expectancies than other western nations, one would think there would be vast opportunities for the U.S. healthcare industry to rein in costs, weed out inefficiency, and improve outcomes. Instead of yielding to “regression toward the mean,” however, the highest global per capita healthcare machine marches to 20 Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Biomarkets: Looking For The Hole In The Donut

synthetic biology

This piece by Allan L. Shaw was originally published in Life Science Leader. The biopharma sector has enjoyed increased market success over the last few years. And while some may be tempted to bask in the optimistic “bio-euphoria,” others question whether the industry might be in the midst of a market bubble. What led to this current period of biopharma success, despite the industry’s inherent risks (e.g. scientific, clinical, regulatory, and commercial)? Several factors contributed Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Warning: Don’t Let Bio-Euphoria Distract You from Being Disciplined

DNA

This piece by Allan L. Shaw was originally published in Life Science Leader. We currently in a period I call “bio-euphoria,” in which the biopharmaceutical industry is experiencing growth in almost every area from market performance to patient-focused legislation. In parallel to this positive momentum, there has also been a notable shift in management and operational strategy by Big Pharma companies in an attempt to keep evolving with the market. These companies are taking creative Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Life Science Leader Asks: What Biopharma Trends Should Pharma Execs Be Paying Attention To?

Life Science Leader

In my last installment of this four-part series interviewing Peter Young, executive-in-residence with A.M. Pappas & Associates, I asked what trends should biopharma execs be paying greater attention to and why. Check out my interview to get insights from Peter on upcoming trends! Peter’s session, Inventing Your Own Hub: Evolving Institutional Models for Translational Medicine, will be taking plan June 16 from 3:30 p.m.-4:45 p.m. in room 105AB. If you missed the earlier segments in this series, here is Part 1, Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Life Science Leader Asks: What Areas Are Often Overlooked by Academics Turned Biotech Entrepreneurs?

Life Science Leader

In my third installment of a four-part series interviewing Peter Young, executive-in-residence with A.M. Pappas & Associates, he shared missteps made by academics aspiring to become entrepreneurs and also offered up some advice on partnering with VCs. Check out my interview, which will include lessons that won’t be a part of his 2015 BIO International Convention session, Inventing Your Own Hub: Evolving Institutional Models for Translational Medicine, (June 16, 3:30 p.m.-4:45 p.m., room 105AB) Here is Part 1, Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,